Research progress in the treatment of cancer patients with positive NTRK gene fusion with larotrectinib
10.3969/j.issn.1000-8179.2019.11.362
- VernacularTitle:拉罗替尼治疗NTRK基因融合阳性癌症患者的研究进展
- Author:
Xiangchong LUO
1
;
Jingjing LIU
;
Gaofeng LI
Author Information
1. 曲靖市第二人民医院心胸外科(云南省曲靖市655000)
- Keywords:
larotrectinib;
malignant tumor;
gene fusion;
molecular targeted drugs
- From:
Chinese Journal of Clinical Oncology
2019;46(11):575-580
- CountryChina
- Language:Chinese
-
Abstract:
Larotrectinib (also called LOxO-101, ARRY-470, and VITRAKVI?) is a kind of new high selective and broad-spectrum small molecule that is administered orally. Larotrectinib is tropomyosin receptor kinase (TRK) inhibitor and is used in the treatment of neuro-trophin tyrosine kinase receptor (NTRK) gene fusion in children and in adults. Based on use of larotrectinib against solid tumor in a vari-ety of NTRK gene fusion, larotrectinib has a good curative effect and security. On November 27, 2018, the drug was approved by the Food and Drug Administration (FDA) for the first time in the world. It is used in the treatment of no unknown drug resistant mutations, a broader shift, or partial surgical treatment, and after the treatment of disease progress of NTRK gene fusion in children and adult pa-tients with solid tumor. This article reviews the latest research progress in the research background, structure, and mechanism of ac-tion, clinical trials, adverse reactions and treatment, and drug resistance mechanism of larotrectinib.
